Profile data is unavailable for this security.
About the company
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulation and active pharmaceutical ingredients (APIs). It produces a comprehensive, diverse and complementary portfolio of generic and specialty medicines targeting a wide spectrum of chronic and acute treatments. The Company's vertically integrated network enables it to produce a wide range of pharmaceuticals, including oncology, hormones, peptides, and steroidal drugs. The Company also has a product portfolio in RoW markets, including injectables, hospital products and retail products. It offers a variety of dosage forms, including orals, creams, ointments, injectables, sprays, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, Yonsa, Sezaby and Sprinkle portfolio.
- Revenue in INR (TTM)474.45bn
- Net income in INR89.06bn
- Incorporated1993
- Employees41.00k
- LocationSun Pharmaceutical Industries LtdSun House, CTS No. 201 B/1,, Western ExpMUMBAI 400 093IndiaIND
- Phone+91 2 243244324
- Fax+91 2 243244343
- Websitehttps://sunpharma.com/
Mergers & acquisitions
Acquired company | SUNPHARMA:NSI since announced | Transaction value |
---|---|---|
Taro Pharmaceutical Industries Ltd | 54.62% | 347.79m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lupin Ltd | 200.11bn | 19.14bn | 781.98bn | 18.97k | 40.96 | 5.47 | 24.96 | 3.91 | 41.89 | 41.89 | 437.85 | 313.60 | 0.8524 | 1.41 | 4.36 | -- | 8.24 | 1.43 | 13.34 | 2.22 | 66.80 | 59.70 | 9.67 | 2.04 | 0.9991 | 8.64 | 0.1689 | 79.28 | 20.25 | 6.41 | 345.15 | 30.18 | -1.17 | 9.86 |
Mankind Pharma Ltd | 103.35bn | 19.13bn | 844.20bn | 18.47k | 44.18 | 9.02 | 36.08 | 8.17 | 47.69 | 47.69 | 257.65 | 233.73 | -- | -- | -- | -- | -- | -- | -- | -- | 68.94 | -- | 18.79 | -- | 2.37 | 116.65 | 0.0212 | -- | 18.12 | -- | 49.23 | -- | -- | -- |
Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 901.53bn | 13.57k | 59.94 | -- | 39.21 | 8.61 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
Dr Reddy's Laboratories Ltd | 280.11bn | 55.78bn | 977.98bn | 24.83k | 17.55 | 3.46 | 13.88 | 3.49 | 334.61 | 334.61 | 1,680.33 | 1,696.70 | 0.7874 | 1.46 | 3.67 | -- | 15.68 | 11.37 | 21.05 | 16.02 | 70.69 | 66.52 | 19.91 | 14.63 | 1.92 | 41.27 | 0.0662 | 16.40 | 13.54 | 12.64 | 23.75 | 23.39 | 26.78 | 14.87 |
Divi's Laboratories Ltd | 74.93bn | 13.83bn | 1.08tn | 16.95k | 77.89 | -- | 61.46 | 14.38 | 52.11 | 52.11 | 282.31 | -- | -- | -- | -- | 4,420,514.00 | -- | 18.50 | -- | 20.48 | 59.23 | 57.21 | 18.46 | 27.90 | -- | -- | -- | 31.31 | -13.31 | 14.70 | -38.41 | 15.76 | 11.55 | 24.57 |
Zydus Lifesciences Ltd | 195.47bn | 38.37bn | 1.09tn | 23.03k | 28.50 | 5.48 | 23.66 | 5.56 | 37.91 | 38.14 | 193.16 | 197.11 | 0.7103 | 1.82 | 4.06 | -- | 13.92 | 9.05 | 19.29 | 14.01 | 68.14 | 62.16 | 19.60 | 14.33 | 1.51 | 22,696.00 | 0.0351 | 16.48 | 13.40 | 8.23 | 95.25 | 15.72 | -3.03 | -3.04 |
Cipla Ltd | 257.74bn | 41.22bn | 1.20tn | 26.62k | 29.05 | 4.48 | 22.99 | 4.64 | 51.02 | 51.02 | 319.08 | 330.77 | 0.829 | 1.70 | 5.84 | -- | 13.37 | 10.09 | 16.16 | 12.40 | 65.78 | 59.69 | 16.12 | 12.66 | 2.71 | 58.30 | 0.0205 | 20.79 | 13.28 | 9.51 | 47.10 | 21.96 | 20.68 | 34.08 |
Sun Pharmaceutical Industries Ltd | 474.45bn | 89.06bn | 3.69tn | 41.00k | 41.48 | -- | 31.90 | 7.78 | 37.11 | 37.11 | 197.73 | -- | -- | -- | -- | 11,571,860.00 | -- | 6.31 | -- | 9.02 | 77.80 | 70.08 | 18.97 | 12.17 | -- | 52.77 | -- | 39.54 | 13.53 | 10.62 | 158.91 | 29.24 | 1.24 | 41.88 |
Holder | Shares | % Held |
---|---|---|
ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 86.44m | 3.60% |
Life Insurance Corporation of India (Investment Portfolio)as of 13 Sep 2023 | 72.27m | 3.01% |
SBI Funds Management Ltd.as of 30 Apr 2024 | 54.64m | 2.28% |
The Vanguard Group, Inc.as of 09 May 2024 | 42.39m | 1.77% |
BlackRock Fund Advisorsas of 09 May 2024 | 26.06m | 1.09% |
Norges Bank Investment Managementas of 30 Sep 2023 | 24.70m | 1.03% |
GQG Partners LLCas of 31 Mar 2024 | 23.31m | 0.97% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Apr 2024 | 21.53m | 0.90% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Apr 2024 | 19.73m | 0.82% |
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 09 May 2024 | 18.20m | 0.76% |